Retatrutide, a new dual stimulator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising results in initial patient assessments . Ongoing inquiry https://socialtechnet.com/story6933924/retatrutide-emerging-investigations-and-projected-therapeutic-applications